-
Mashup Score: 1FDA Approves Ivosidenib in IDH1-Mutated MDS - 6 month(s) ago
Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Luspatercept, which is supported by results from the phase 3 COMMANDS trial presented at 2023 ASCO, is now available for patients with low-risk myelodysplastic syndrome.
Source: www.cancernetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Luspatercept, the use of which is supported by results from the phase 3 COMMANDS trial presented at 2023 ASCO, is now available for patients with low-risk myelodysplastic syndrome. @FDA @FDAOncology #hemcsm https://t.co/Nscxurxfw0
-
-
Mashup Score: 0Elranatamab Receives Accelerated Approval in R/R Multiple Myeloma - 8 month(s) ago
Elranatamab-bcmm is now approved for patients with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.
Source: www.cancernetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The @FDA has granted accelerated approval to elranatamab-bcmm for patients with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy. @FDAOncology #mmcsm #hemcsm https://t.co/quDstx32el
-
-
Mashup Score: 0
Nirav N. Shah, MD, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nirav N. Shah, MD, of @MedicalCollege, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies #hemcsm https://t.co/Vi5nnPoeLU https://t.co/uv5lTBMRyN
-
-
Mashup Score: 0
Nirav N. Shah, MD, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nirav N. Shah, MD, of @MedicalCollege, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies #hemcsm https://t.co/tbUHT5hMOl https://t.co/6bBnT03JEE
-
-
Mashup Score: 0
Nirav N. Shah, MD, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nirav N. Shah, MD, of @MedicalCollege, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies #hemcsm https://t.co/KvkQ05ZYZP https://t.co/Lze0Mf2SWs
-
-
Mashup Score: 0
Nirav N. Shah, MD, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nirav N. Shah, MD, of @MedicalCollege, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies #hemcsm https://t.co/QN5kqo5MUG
-
-
Mashup Score: 0Avapritinib Meets Primary and Secondary End Points in PIONEER Trial in Non-Advanced Systemic Mastocytosis - 2 year(s) ago
Treatment with avapritinib led to clinically meaningful and statistically significant improvements in patient-reported symptoms and objective measures of mast cell burden in patients with non-advanced systemic mastocytosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Avapritinib Meets Primary and Secondary End Points in PIONEER Trial in Non-Advanced Systemic Mastocytosis #hemcsm #oncology https://t.co/whRCvBOyzo
-
-
Mashup Score: 1
A pediatric patient with severe transplant-associated thrombotic microangiopathy responded to treatment with narsoplimab after experiencing disease progression on eculizumab.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A pediatric patient with severe transplant-associated thrombotic microangiopathy responded to treatment with narsoplimab after experiencing disease progression on eculizumab. @EmoryMedicine #hemcsm https://t.co/kiu0D6hCwF https://t.co/agXJBLOLHf
-
-
Mashup Score: 0
A pediatric patient with severe transplant-associated thrombotic microangiopathy responded to treatment with narsoplimab after experiencing disease progression on eculizumab.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to findings presented in a poster during the 48th Annual Meeting of the EBMT, a pediatric patient with severe TA-TMA responded to treatment with narsoplimab after experiencing disease progression on eculizumab. @EmoryMedicine #hemcsm https://t.co/dOBQSyZOMN https://t.co/RwQaxWocxt
-
Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation. #hemcsm https://t.co/3su3svTKs0